Fiocruz chosen by WHO as mRNA vaccines hub
The World Health Organization (WHO) has chosen Brazil’s research organization Fiocruz and its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) as a hub for the development and production of vaccines using mRNA in Latin America.
This unit was chosen due to promising advances in the technological development of an mRNA vaccine against COVID-19, currently in pre-clinical stage. The initiative used the resources of Brazil’s Ministry of Health for its development.
"Developing a Fiocruz mRNA vaccine is a crucial step to make sure Brazil holds the technological domain of two fundamental platforms for the advancement of immunobiological development"The choice was the result of a search launched on April 16, 2021, with the goal of increasing production capacity and extending access to vaccines against COVID-19 in the Americas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze